CanSino Biologics CASBF Stock
CanSino Biologics Price Chart
CanSino Biologics CASBF Financial and Trading Overview
| CanSino Biologics stock price | 2.86 USD |
| Previous Close | 3.1 USD |
| Open | 4.1 USD |
| Bid | 3.1 USD x 230000 |
| Ask | 3.7 USD x 30000 |
| Day's Range | 3.97 - 4.1 USD |
| 52 Week Range | 2.86 - 6.99 USD |
| Volume | 1.2K USD |
| Avg. Volume | 66 USD |
| Market Cap | 980.76M USD |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | 198.5 |
| EPS (TTM) | 0.02 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | July 13, 2022 |
| 1y Target Est | N/A |
CASBF Valuation Measures
| Enterprise Value | -541975040 USD |
| Trailing P/E | 198.5 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.8748768 |
| Price/Book (mrq) | 1.3493493 |
| Enterprise Value/Revenue | -0.483 |
| Enterprise Value/EBITDA | -9.324 |
Trading Information
CanSino Biologics Stock Price History
| Beta (5Y Monthly) | 1.16 |
| 52-Week Change | -10.62% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 6.99 USD |
| 52 Week Low | 2.86 USD |
| 50-Day Moving Average | 3.63 USD |
| 200-Day Moving Average | 4.64 USD |
CASBF Share Statistics
| Avg. Volume (3 month) | 66 USD |
| Avg. Daily Volume (10-Days) | 10 USD |
| Shares Outstanding | 132.67M |
| Float | 159.89M |
| Short Ratio | N/A |
| % Held by Insiders | 26.85% |
| % Held by Institutions | 16.19% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -0.090% |
| Operating Margin (ttm) | -15.18% |
| Gross Margin | 75.36% |
| EBITDA Margin | 5.18% |
Management Effectiveness
| Return on Assets (ttm) | -0.82% |
| Return on Equity (ttm) | -0.020% |
Income Statement
| Revenue (ttm) | 1.12B USD |
| Revenue Per Share (ttm) | 4.33 USD |
| Quarterly Revenue Growth (yoy) | 38.70% |
| Gross Profit (ttm) | 844.83M USD |
| EBITDA | 58.13M USD |
| Net Income Avi to Common (ttm) | -1006131 USD |
| Diluted EPS (ttm) | 0.02 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.41B USD |
| Total Cash Per Share (mrq) | 9.76 USD |
| Total Debt (mrq) | 1.16B USD |
| Total Debt/Equity (mrq) | 23.59 USD |
| Current Ratio (mrq) | 4.107 |
| Book Value Per Share (mrq) | 2.942159 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 37.76M USD |
| Levered Free Cash Flow (ttm) | -351570848 USD |
Profile of CanSino Biologics
| Country | United States |
| State | N/A |
| City | Tianjin |
| Address | 401-420, Biomedical Park |
| ZIP | 300457 |
| Phone | 86 022 5821 3600 |
| Website | https://cansinotech.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 1134 |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Q&A For CanSino Biologics Stock
What is a current CASBF stock price?
CanSino Biologics CASBF stock price today per share is 2.86 USD.
How to purchase CanSino Biologics stock?
You can buy CASBF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CanSino Biologics?
The stock symbol or ticker of CanSino Biologics is CASBF.
Which industry does the CanSino Biologics company belong to?
The CanSino Biologics industry is Drug Manufacturers - Specialty & Generic.
How many shares does CanSino Biologics have in circulation?
The max supply of CanSino Biologics shares is 247.04M.
What is CanSino Biologics Price to Earnings Ratio (PE Ratio)?
CanSino Biologics PE Ratio is 143.00000000 now.
What was CanSino Biologics earnings per share over the trailing 12 months (TTM)?
CanSino Biologics EPS is 0.02 USD over the trailing 12 months.
Which sector does the CanSino Biologics company belong to?
The CanSino Biologics sector is Healthcare.